Centre Hospitalier Sud Francilien
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-09-30 | NCT06918002 | |
| Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-07-17 | NCT02416388 | |
| EWALL-PH OBSERVARTORY 2022 | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Not stated | 2026-07-06 | NCT07684131 | |
| Identification of Genetic Variants Associated With Unexpected Infant Death Syndrome | Death, Death, Sudden, Infant Death, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sudden Infant Death | Recruiting | Not stated | 2026-06-18 | NCT06244433 | |
| Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older | diffuse large B-cell lymphoma | Active, not recruiting | Phase 2 | 2026-06-04 | NCT04974216 | |
| Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Not applicable | 2026-05-26 | NCT07124858 | |
| A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL | LAL | Not yet recruiting | Phase 2 | 2026-04-17 | NCT07522801 | |
| Role of High-Throughput Whole Genome Sequencing for the Diagnosis and Care of Atypical Diabetes | Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diabetes mellitus, disease, endocrine system disorder, glucose metabolism disease, metabolic disease | Recruiting | Not applicable | 2026-04-09 | NCT06570278 | |
| COLPAC (RaDiCo Cohort) (RaDiCo-COLPAC) | gallbladder disease 1 | Active, not recruiting | Not stated | 2026-02-12 | NCT05961826 | |
| Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2025-10-03 | NCT04777916 | |
| Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2025-07-09 | NCT02885753 | |
| MInimal Residual Disease Adapted Strategy | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2024-11-07 | NCT04934475 | |
| Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations. | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Not applicable | 2024-03-06 | NCT04144387 |